STEAP2 and neoplasm: Encouragingly, our STEAP2 IHC data in tumor samples indicated high homogeneity of the target, as 93% of CRPC, 89% of lymph node metastatic, and 85% of bone metastatic patient samples showed ≥75% of the tumor-expressing membrane STEAP2 (Figure 2B).